Trifluridine
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mycobacterium Avium-Intracellulare Infection
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Trial Timeline
— → —
NCT ID
NCT00002037About Trifluridine
Trifluridine is a pre-clinical stage product being developed by Amgen for Mycobacterium Avium-Intracellulare Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00002037. Target conditions include Mycobacterium Avium-Intracellulare Infection, HIV Infections.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00002037 | Pre-clinical | Completed |
Competing Products
20 competing products in Mycobacterium Avium-Intracellulare Infection